IN8BIO INC (INAB)

These stocks are moving in today's after hours session

After hours stock analysis on 2024-12-20: top gainers and losers in today's session.

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

IN8bio Reports Continued Progression-Free Survival in Phase 1 Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 ASH Conference...

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T...

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual...

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights...

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting...

IN8bio Announces Pricing of $12.4 Million Private Placement

IN8bio Announces Pricing of $12.4 Million Private Placement ...

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia ...

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference...

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

INAB Stock Earnings: IN8bio Misses EPS for Q2 2024

INAB stock results show that IN8bio missed analyst estimates for earnings per share the second quarter of 2024.

INAB Stock Earnings: IN8bio Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips IN8bio (NASDAQ:INAB) just reported results for the second quarter of 2024.IN8bi...

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative...

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 ...

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting...

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024...

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting...

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress...

INAB Stock Earnings: IN8bio Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips IN8bio (NASDAQ:INAB) just reported results for the first quarter of 2024.IN8bio...

INAB Stock Earnings: IN8bio Misses EPS for Q1 2024

INAB stock results show that IN8bio missed analyst estimates for earnings per share the first quarter of 2024.

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights ...

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma...

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference...